Clinical-stage biopharmaceutical company Alto Neuroscience Inc (NYSE:ANRO) announced on Friday that the US Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS).
CIAS is a core feature of schizophrenia with no currently approved treatments, significantly affecting daily functioning and quality of life.
ALTO-101 is a novel phosphodiesterase-4 (PDE4) inhibitor that has shown pro-cognitive effects in healthy volunteers. By inhibiting PDE4, ALTO-101 increases cAMP levels in the brain, potentially enhancing neuronal signalling and synaptic plasticity, which are critical to learning and memory.
Fast Track designation is intended to accelerate the development and review of therapies for serious conditions with unmet medical needs. This status may allow for more frequent FDA interactions and potential eligibility for accelerated approval and priority review.
ALTO-101 is currently being evaluated in an ongoing Phase 2 proof-of-concept study in patients with CIAS.
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Pharming receives FDA priority review for leniolisib in children with APDS
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe